OncoMatch/Clinical Trials/NCT06237920
Stage II-IIIa Urothelial Cancer Randomizing Pre-operative Nivolumab With or Without Relatlimab
Is NCT06237920 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Nivolumab and Relatlimab for urologic neoplasms.
Treatment: Nivolumab · Relatlimab — This is a non-blinded phase 2 trial in Stage II-IIIa urothelial cancer randomizing pre-operative nivolumab with or without relatlimab to assess whether bladder preservation after dual immunotherapy would be a viable treatment option for patients responding to treatment
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Urothelial Carcinoma
Disease stage
Required: Stage CT2-4AN0M0, CT1-4AN1M0
Performance status
WHO 0–1
Prior therapy
Cannot have received: intravenous systemic therapy
Previous intravenous systemic therapy or radiotherapy for UC
Cannot have received: radiotherapy
Previous intravenous systemic therapy or radiotherapy for UC
Cannot have received: CTLA-4 inhibitor
Prior CTLA-4, LAG3 or PD-1/PD-L1-targeting immunotherapy
Cannot have received: LAG3 inhibitor
Prior CTLA-4, LAG3 or PD-1/PD-L1-targeting immunotherapy
Cannot have received: anti-PD-1 therapy
Prior CTLA-4, LAG3 or PD-1/PD-L1-targeting immunotherapy
Cannot have received: anti-PD-L1 therapy
Prior CTLA-4, LAG3 or PD-1/PD-L1-targeting immunotherapy
Lab requirements
Blood counts
WBC ≥ 2.0x10^9/L, Platelets ≥100 x10^9/L, Hemoglobin ≥5.5 mmol/L
Kidney function
GFR >30 ml/min
Liver function
AST ≤ 1.5 x ULN, ALT ≤1.5 x ULN, Bilirubin ≤1.5 X ULN
Screening laboratory values must meet the following criteria: WBC ≥ 2.0x109/L, Platelets ≥100 x109/L, Hemoglobin ≥5.5 mmol/L, GFR>30 ml/min, AST ≤ 1.5 x ULN, ALT ≤1.5 x ULN, Bilirubin ≤1.5 X ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06237920 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
What disease stage is eligible?
Stage CT2-4AN0M0 or CT1-4AN1M0 is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages